"Doylestown Health Cardiology offers compassionate, responsive heart care using state-of-the-art technology, and provides patient education in a professional, attentive environment. Doylestown Health Cardiology includes experienced, board-certified physicians, nurse practitioners, physician assistants and professional staff who work as a team to meet the needs of each individual patient."

During the past decade, Central Bucks Cardiology conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 5 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Central Bucks Cardiology" #1 sponsor was "Boehringer Ingelheim" with 2 trials, followed by "Brigham and Women's Hospital" with 1 trials sponsored, "Bristol-Myers Squibb" with 1 trials sponsored, "Cardionet" with 1 trials sponsored and "Gilead Sciences" with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Central Bucks Cardiology" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator and "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Central Bucks Cardiology" are "Atrial Fibrillation" (3 trials), "Angina Pectoris" (1 trials), "Anti-coagulation Therapy" (1 trials), "Atrial Flutter" (1 trials) and "Cardiovascular Disease" (1 trials). Many other conditions were trialed in "Central Bucks Cardiology" in a lesser frequency.

Most popular intervention types in "Central Bucks Cardiology" are "Drug" (4 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Linagliptin" (1 trials), "Methotrexate" (1 trials), "Protecta DR-ICD or CRT-D" (1 trials) and "Protecta VR-ICD" (1 trials). Other intervention names were less common.

The vast majority of trials in "Central Bucks Cardiology" are 8 trials for "All" genders.

Currently, there are NaN active trials in "Central Bucks Cardiology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Central Bucks Cardiology, 1 suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Central Bucks Cardiology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".